1. Dr Ashleys to acquire Impact BioMedical in a strategic merger. 2. Transaction enhances IBO's market reach with Dr Ashleys' global capabilities. 3. New entity to be named Dr Ashleys Limited post-merger, listing on NYSE. 4. Leadership highlights innovative treatments and expanded global health impact. 5. Merger subject to shareholder approval and regulatory conditions.

1. Ryde acquired 40% of Atoll, enhancing its EV portfolio and sustainability efforts. 2. Singapore's EV market is projected to reach $564 million by 2030. 3. Ryde's investment aligns with government plans for a low-emission transport ecosystem. 4. Collaboration with Atoll supports deeper EV integration within Ryde's services. 5. The acquisition positions Ryde for future regional expansion in green mobility.

1. C&S to acquire SpartanNash for $26.90 per share, $1.77 billion total. 2. Transaction offers 52.5% premium over SpartanNash's last closing price. 3. Merger aims to enhance efficiency and lower grocery prices in the U.S. 4. Transaction approved by both companies' Boards; expected to close late 2025. 5. SpartanNash's quarterly dividend of $0.22 per share will continue.

1. Couchbase to be acquired by Haveli Investments for $1.5 billion. 2. Shareholders will receive $24.50 per share, a 67% premium. 3. Couchbase will become privately held post-transaction completion. 4. Transaction includes a 'go-shop' period until June 23, 2025. 5. Merger may face regulatory approvals and shareholder votes.

1. VNCE's Q1 2025 net sales fell 2.1%, totaling $57.9 million. 2. Gross margins decreased due to higher freight and handling costs. 3. SG&A expenses rose to 58% of sales, increasing operational losses. 4. The outlook for Q2 2025 predicts flat to down 3% in sales. 5. VNCE maintains a strategic partnership with Authentic Brands Group.

1. Scholar Rock announced positive EMBRAZE trial results for apitegromab. 2. Apitegromab preserved 4.2 pounds of lean mass during weight loss treatment. 3. The drug was well tolerated with no serious adverse events reported. 4. SRK-439 is planned for IND application submission in second half of the year. 5. Results validate the potential of myostatin inhibitors in treating obesity.

1. Jeffs' Brands acquires Fort Products, enhancing e-commerce presence. 2. Impact will issue 100M shares to Jeffs' Brands post-acquisition. 3. Transaction values Fort between CAD$16.86M and CAD$20.59M. 4. Completion expected by July 7, 2025, subject to approvals. 5. Jeffs' Brands aims for substantial growth in global retail markets.

1. GRAIL reports positive results from PATHFINDER 2 study on Galleri. 2. Galleri improved cancer detection significantly compared to the previous PATHFINDER study. 3. Safety concerns were minimal in the PATHFINDER 2 study results. 4. Galleri's FDA premarket approval is anticipated by early 2026. 5. Results will be showcased at an international oncology meeting later this year.

1. TEN's Q1 2025 net income reached $38 million, or $1.04 EPS. 2. Awarded $2 billion contract to build nine DP2 shuttle tankers. 3. Current fleet backlog stands at approximately $3.7 billion. 4. Dividends exceed $900 million since TEN's 2002 NYSE listing. 5. Utilization increased to 97.2% from 91.3% year-over-year.

1. GXO's acquisition of Wincanton cleared with minor divestment requirements. 2. Full-year guidance increased for organic revenue, EBITDA, and EPS. 3. Integration with Wincanton expected to boost growth and operational synergies. 4. Collaborative efforts allowed on aerospace and defense projects immediately. 5. Positive adjustment reflects stronger volumes and productivity across operations.